Susquehanna upgrades Vertex Pharmaceuticals (Nasdaq: VRTX) to Positive. Price target $31.

Susquehanna analyst says, "Our target/valuation for Vertex ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE